The 2‐oxoglutarate/malate carrier extends the family of mitochondrial carriers capable of fatty acid and 2,4‐dinitrophenol‐activated proton transport

Author:

Žuna Kristina1ORCID,Tyschuk Tatyana1,Beikbaghban Taraneh1,Sternberg Felix1ORCID,Kreiter Jürgen1ORCID,Pohl Elena E.1ORCID

Affiliation:

1. Physiology and Biophysics, Department of Biological Sciences and Pathobiology University of Veterinary Medicine Vienna Austria

Abstract

AbstractAimsMetabolic reprogramming in cancer cells has been linked to mitochondrial dysfunction. The mitochondrial 2‐oxoglutarate/malate carrier (OGC) has been suggested as a potential target for preventing cancer progression. Although OGC is involved in the malate/aspartate shuttle, its exact role in cancer metabolism remains unclear. We aimed to investigate whether OGC may contribute to the alteration of mitochondrial inner membrane potential by transporting protons.MethodsThe expression of OGC in mouse tissues and cancer cells was investigated by PCR and Western blot analysis. The proton transport function of recombinant murine OGC was evaluated by measuring the membrane conductance (Gm) of planar lipid bilayers. OGC‐mediated substrate transport was measured in proteoliposomes using 14C‐malate.ResultsOGC increases proton Gm only in the presence of natural (long‐chain fatty acids, FA) or chemical (2,4‐dinitrophenol) protonophores. The increase in OGC activity directly correlates with the increase in the number of unsaturated bonds of the FA. OGC substrates and inhibitors compete with FA for the same protein binding site. Arginine 90 was identified as a critical amino acid for the binding of FA, ATP, 2‐oxoglutarate, and malate, which is a first step towards understanding the OGC‐mediated proton transport mechanism.ConclusionOGC extends the family of mitochondrial transporters with dual function: (i) metabolite transport and (ii) proton transport facilitated in the presence of protonophores. Elucidating the contribution of OGC to uncoupling may be essential for the design of targeted drugs for the treatment of cancer and other metabolic diseases.

Funder

Austrian Science Fund

Publisher

Wiley

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3